1
|
Spanagel R, Bach P, Banaschewski T, Beck A, Bermpohl F, Bernardi RE, Beste C, Deserno L, Durstewitz D, Ebner‐Priemer U, Endrass T, Ersche KD, Feld G, Gerchen MF, Gerlach B, Goschke T, Hansson AC, Heim C, Kiebel S, Kiefer F, Kirsch P, Kirschbaum C, Koppe G, Lenz B, Liu S, Marxen M, Meinhardt MW, Meyer‐Lindenberg A, Montag C, Müller CP, Nagel WE, Oliveria AMM, Owald D, Pilhatsch M, Priller J, Rapp MA, Reichert M, Ripke S, Ritter K, Romanczuk‐Seiferth N, Schlagenhauf F, Schwarz E, Schwöbel S, Smolka MN, Soekadar SR, Sommer WH, Stock A, Ströhle A, Tost H, Vollstädt‐Klein S, Walter H, Waschke T, Witt SH, Heinz A. The ReCoDe addiction research consortium: Losing and regaining control over drug intake-Findings and future perspectives. Addict Biol 2024; 29:e13419. [PMID: 38949209 PMCID: PMC11215792 DOI: 10.1111/adb.13419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 05/15/2024] [Accepted: 05/21/2024] [Indexed: 07/02/2024]
Abstract
Substance use disorders (SUDs) are seen as a continuum ranging from goal-directed and hedonic drug use to loss of control over drug intake with aversive consequences for mental and physical health and social functioning. The main goals of our interdisciplinary German collaborative research centre on Losing and Regaining Control over Drug Intake (ReCoDe) are (i) to study triggers (drug cues, stressors, drug priming) and modifying factors (age, gender, physical activity, cognitive functions, childhood adversity, social factors, such as loneliness and social contact/interaction) that longitudinally modulate the trajectories of losing and regaining control over drug consumption under real-life conditions. (ii) To study underlying behavioural, cognitive and neurobiological mechanisms of disease trajectories and drug-related behaviours and (iii) to provide non-invasive mechanism-based interventions. These goals are achieved by: (A) using innovative mHealth (mobile health) tools to longitudinally monitor the effects of triggers and modifying factors on drug consumption patterns in real life in a cohort of 900 patients with alcohol use disorder. This approach will be complemented by animal models of addiction with 24/7 automated behavioural monitoring across an entire disease trajectory; i.e. from a naïve state to a drug-taking state to an addiction or resilience-like state. (B) The identification and, if applicable, computational modelling of key molecular, neurobiological and psychological mechanisms (e.g., reduced cognitive flexibility) mediating the effects of such triggers and modifying factors on disease trajectories. (C) Developing and testing non-invasive interventions (e.g., Just-In-Time-Adaptive-Interventions (JITAIs), various non-invasive brain stimulations (NIBS), individualized physical activity) that specifically target the underlying mechanisms for regaining control over drug intake. Here, we will report on the most important results of the first funding period and outline our future research strategy.
Collapse
Affiliation(s)
- Rainer Spanagel
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Patrick Bach
- Department of Addictive Behavior and Addiction MedicineCentral Institute of Mental HealthMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Tobias Banaschewski
- Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Anne Beck
- Department of Psychology, Faculty of HealthHealth and Medical University PotsdamPotsdamGermany
| | - Felix Bermpohl
- Department of Psychiatry and PsychotherapyCharité Campus St. Hedwig HospitalBerlinGermany
| | - Rick E. Bernardi
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Christian Beste
- Cognitive NeurophysiologyDepartment of Child and Adolescent Psychiatry and the University Neuropsychology Center (UNC)DresdenGermany
| | - Lorenz Deserno
- Department of Child and Adolescent Psychiatry, Psychotherapy and PsychosomaticsUniversity Hospital and University WürzburgWürzburgGermany
| | - Daniel Durstewitz
- Department of Theoretical NeuroscienceCentral Institute of Mental HealthMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Ulrich Ebner‐Priemer
- Mental mHealth Lab, Institute of Sports and Sports ScienceKarlsruhe Institute of TechnologyKarlsruheGermany
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Tanja Endrass
- Faculty of PsychologyTechnische Universität DresdenDresdenGermany
| | - Karen D. Ersche
- Department of Addictive Behavior and Addiction MedicineCentral Institute of Mental HealthMannheimGermany
- Department of PsychiatryUniversity of CambridgeCambridgeUK
| | - Gordon Feld
- Department of Clinical PsychologyCentral Institute of Mental HealthMannheimGermany
| | | | - Björn Gerlach
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Thomas Goschke
- Faculty of PsychologyTechnische Universität DresdenDresdenGermany
| | - Anita Christiane Hansson
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Christine Heim
- Institute of Medical PsychologyCharité, Universitätsmedizin BerlinBerlinGermany
| | - Stefan Kiebel
- Cognitive Computational Neuroscience, Faculty of PsychologyTechnische Universität DresdenDresdenGermany
| | - Falk Kiefer
- Department of Addictive Behavior and Addiction MedicineCentral Institute of Mental HealthMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Peter Kirsch
- Department of Clinical PsychologyCentral Institute of Mental HealthMannheimGermany
| | - Clemens Kirschbaum
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Georgia Koppe
- Department of Theoretical NeuroscienceCentral Institute of Mental HealthMannheimGermany
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- Hector Institute for Artificial Intelligence in Psychiatry, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Bernd Lenz
- Department of Addictive Behavior and Addiction MedicineCentral Institute of Mental HealthMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Shuyan Liu
- Department of Psychiatry and NeurosciencesCampus Charité MitteBerlinGermany
| | - Michael Marxen
- Department of Psychiatry and PsychotherapyTechnische Universität DresdenDresdenGermany
| | - Marcus W. Meinhardt
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Andreas Meyer‐Lindenberg
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Christiane Montag
- Department of Psychiatry and PsychotherapyCharité Campus St. Hedwig HospitalBerlinGermany
| | - Christian P. Müller
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- Department of Psychiatry and PsychotherapyUniversity Clinic, Friedrich‐Alexander‐University of Erlangen‐NürnbergErlangenGermany
| | - Wolfgang E. Nagel
- Center for Information Services and High Performance ComputingDresdenGermany
| | - Ana M. M. Oliveria
- Department of Molecular and Cellular Cognition Research, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - David Owald
- Institute of NeurophysiologyCharité – Universitätsmedizin BerlinBerlinGermany
| | - Maximilian Pilhatsch
- Department of Psychiatry and PsychotherapyTechnische Universität DresdenDresdenGermany
| | - Josef Priller
- Department of Psychiatry and PsychotherapyTechnical University of MunichMunichGermany
- German Center for Mental Health (DZPG), Partner Site Munich‐AugsburgGermany
| | - Michael A. Rapp
- Social and Preventive Medicine, Research Area Cognitive SciencesUniversity of PotsdamPotsdamGermany
- German Center for Mental Health (DZPG), Partner Site Berlin‐PotsdamBerlinGermany
| | - Markus Reichert
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- Department of eHealth and Sports Analytics, Faculty of Sport ScienceRuhr University BochumBochumGermany
| | - Stephan Ripke
- Department of Psychiatry and NeurosciencesCampus Charité MitteBerlinGermany
| | - Kerstin Ritter
- Department of Psychiatry and NeurosciencesCampus Charité MitteBerlinGermany
| | - Nina Romanczuk‐Seiferth
- Clinical Psychology and Psychotherapy, Department of PsychologyMSB Medical School BerlinBerlinGermany
| | | | - Emanuel Schwarz
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- Hector Institute for Artificial Intelligence in Psychiatry, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Sarah Schwöbel
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Michael N. Smolka
- Department of Psychiatry and PsychotherapyTechnische Universität DresdenDresdenGermany
| | - Surjo R. Soekadar
- Department of Psychiatry and NeurosciencesCampus Charité MitteBerlinGermany
| | - Wolfgang H. Sommer
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- Bethanien Hospital for Psychiatry, Psychosomatics and PsychotherapyGreifswaldGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Ann‐Kathrin Stock
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Andreas Ströhle
- Department of Psychiatry and NeurosciencesCampus Charité MitteBerlinGermany
| | - Heike Tost
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
- German Center for Mental Health (DZPG), Partner Site Mannheim‐Heidelberg‐UlmGermany
| | - Sabine Vollstädt‐Klein
- Department of Addictive Behavior and Addiction MedicineCentral Institute of Mental HealthMannheimGermany
- Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty of MannheimUniversity of HeidelbergMannheimGermany
| | - Henrik Walter
- Department of Psychiatry and NeurosciencesCampus Charité MitteBerlinGermany
| | - Tina Waschke
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
| | - Stephanie H. Witt
- Department of Genetic Epidemiology in Psychiatry, ZIPP BiobankCentral Institute of Mental Health, Medical Faculty MannheimMannheimGermany
| | - Andreas Heinz
- Department of Psychiatry and NeurosciencesCampus Charité MitteBerlinGermany
- German Center for Mental Health (DZPG), Partner Site Berlin‐PotsdamBerlinGermany
| | | |
Collapse
|
2
|
Hayes BB, Reyna VF, Edelson SM. Making decisions one drink at a time and the "just one drink" effect: A fuzzy-trace theory model of harmful drinking. ALCOHOL, CLINICAL & EXPERIMENTAL RESEARCH 2024; 48:889-902. [PMID: 38642331 DOI: 10.1111/acer.15291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 01/19/2024] [Accepted: 02/19/2024] [Indexed: 04/22/2024]
Abstract
BACKGROUND Understanding the decision factors that drive harmful alcohol use among young adults is of practical and theoretical importance. We apply fuzzy-trace theory (FTT) to investigate a potential danger that may arise from the arguably correct notion that a single drink carries no meaningful risk. Decisions that are mentally represented as one drink at a time could contribute to excessive drinking. METHODS College students (N = 351) made a series of decisions to take or decline eight hypothetical drinks presented one at a time. Outcome measures included each decision, recent alcohol consumption (weekly drinks, peak blood alcohol content, and binges), and alcohol-related harms (scores on the Brief Young Adult Alcohol Consequences Questionnaire and Alcohol Use Disorders Identification Test). Linear regression models predicted each outcome from sex, perceived risk of a single drink, perceived risk of heavy drinking, perceived consequences of drinking, and general health-related risk sensitivity. RESULTS Consistent with FTT, decisions to have a first drink and up to four additional drinks in short succession were each associated with lower perceived risk of one drink-a "just-one drink" effect-independent of perceived risks of heavy drinking, perceived consequences of drinking, and general risk sensitivity. Similarly, all measures of recent alcohol consumption and consequent harms were associated with perceived risk of one drink. Participants reporting "zero risk" of a single drink had worse outcomes on all measures than those reporting at least "low risk." CONCLUSIONS Results are consistent with the theoretically informed premise that consumption decisions are typically made one drink at a time rather than by deciding the total number of drinks to be consumed in a sitting. When decisions about alcohol use proceed one drink at a time, a perception of zero risk in a single drink may contribute to heavy drinking.
Collapse
Affiliation(s)
- Bridget B Hayes
- Department of Human Development, Cornell University, Ithaca, New York, USA
| | - Valerie F Reyna
- Department of Human Development, Cornell University, Ithaca, New York, USA
| | - Sarah M Edelson
- Department of Human Development, Cornell University, Ithaca, New York, USA
| |
Collapse
|
3
|
Colzato L, Elmers J, Xu X, Zhou Q, Hommel B, Beste C. Regaining control over opioid use? The potential application of auricular transcutaneous vagus nerve stimulation to improve opioid treatment in China. Addict Biol 2023; 28:e13343. [PMID: 37855071 DOI: 10.1111/adb.13343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 05/18/2023] [Accepted: 09/20/2023] [Indexed: 10/20/2023]
Abstract
Opioid use disorder (OUD) is a critical problem in China and is accompanied by depression and deficits in cognitive control. In China, the most successful intervention for OUD is the community drug rehabilitation where methadone maintenance treatment (MMT) plays a key role. Even though methadone for the treatment of OUD can be helpful, it can cause severe somatic side-effects, which limit its effectivity. Even worse, it can have detrimental effects on cognitive control, which is crucial to regain control over drug intake. Here, we consider the potential use of auricular transcutaneous vagus nerve stimulation (atVNS) as an addition to MMT for opioid withdrawal treatment. Compared to other non-invasive brain stimulation methods, atVNS also targets the locus coeruleus (LC) important for noradrenaline (NA) synthesis. NA is an essential neurotransmitter impacted in opioid withdrawal and also critically involved in cognitive control processes. Its ADD-ON to MMT might be a useful mean to improve mood and enhance cognitive control processes impacted in OUD. We discuss the translational advantages of atVNS in China such as the cultural acceptance of the modality of treatment similar to electroacupuncture. Additionally, the wearability of the ear electrode and at-home self-administration without intense medical supervision makes of atVNS a useful tool to enhance clinical and cognitive outcomes especially in everyday life situation. We discuss how atVNS can be integrated in tele-medical health approaches allowing that innovative treatments can widely be disseminated and continued even in situations of restricted medical access.
Collapse
Affiliation(s)
- Lorenza Colzato
- Cognitive Psychology, Faculty of Psychology, Shandong Normal University, Jinan, China
| | - Julia Elmers
- Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine, TU Dresden, Germany
- Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| | - Xiaolei Xu
- Cognitive Psychology, Faculty of Psychology, Shandong Normal University, Jinan, China
| | - Qiang Zhou
- Department of Psychology, Wenzhou Medical University, Wenzhou, China
| | - Bernhard Hommel
- Cognitive Psychology, Faculty of Psychology, Shandong Normal University, Jinan, China
| | - Christian Beste
- Cognitive Psychology, Faculty of Psychology, Shandong Normal University, Jinan, China
- Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine, TU Dresden, Germany
- Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, TU Dresden, Germany
| |
Collapse
|
4
|
Mellick WH, Tolliver BK, Brenner HM, Anton RF, Prisciandaro JJ. Alcohol Cue Processing in Co-Occurring Bipolar Disorder and Alcohol Use Disorder. JAMA Psychiatry 2023; 80:1150-1159. [PMID: 37556131 PMCID: PMC10413222 DOI: 10.1001/jamapsychiatry.2023.2726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 06/04/2023] [Indexed: 08/10/2023]
Abstract
Importance Reward circuitry dysfunction is a candidate mechanism of co-occurring bipolar disorder and alcohol use disorder (BD + AUD) that remains understudied. This functional magnetic resonance imaging (fMRI) research represents the first evaluation of alcohol cue reward processing in BD + AUD. Objective To determine how alcohol cue processing in individuals with BD + AUD may be distinct from that of individuals with AUD or BD alone. Design, Setting, and Participants This cross-sectional case-control study (April 2013-June 2018) followed a 2 × 2 factorial design and included individuals with BD + AUD, AUD alone, BD alone, and healthy controls. A well-validated visual alcohol cue reactivity fMRI paradigm was administered to eligible participants following their demonstration of 1 week or more of abstinence from alcohol and drugs assessed via serial biomarker testing. Study procedures were completed at the Medical University of South Carolina. Analysis took place between June and August 2022. Main Outcomes and Measures Past-week mood symptoms were rated by clinicians using the Montgomery-Åsberg Depression Rating Scale and Young Mania Rating Scale. The Alcohol Dependence Scale, Obsessive-Compulsive Drinking Scale, and Barratt Impulsiveness Scale were included questionnaires. Functional MRI whole-brain data were analyzed along with percent signal change within a priori regions of interest located in the ventral striatum, dorsal striatum, and ventromedial prefrontal cortex. Exploratory analyses of associations between cue reactivity and select behavioral correlates (alcohol craving, impulsivity, maximum number of alcohol drinks on a single occasion, and days since last alcohol drink) were also performed. Results Of 112 participants, 28 (25.0%) had BD + AUD, 26 (23.2%) had AUD alone, 31 (27.7%) had BD alone, and 27 (24.1%) were healthy controls. The mean (SD) age was 38.7 (11.6) years, 50 (45.5%) were female, 33 (30%) were smokers, and 37 (34.9%) reported recent alcohol consumption. Whole-brain analyses revealed a BD × AUD interaction (F = 10.64; P = .001; η2 = 0.09) within a cluster spanning portions of the right inferior frontal gyrus and insula. Region of interest analyses revealed a main association of BD (F = 8.02; P = .006; η2 = 0.07) within the dorsal striatum. In each instance, individuals with BD + AUD exhibited reduced activation compared with all other groups who did not significantly differ from one another. These hypoactivations were associated with increased impulsivity and obsessive-compulsive alcohol craving exclusively among individuals with BD + AUD. Conclusion and Relevance The findings of this study suggest conceptualizing reward dysfunction in BD + AUD by the potential interaction between blunted reward responsivity and deficient inhibitory control may help guide treatment development strategies. To this end, reduced right inferior frontal gyrus and insula alcohol cue reactivity represents a novel candidate biomarker of BD + AUD that may respond to pharmacological interventions targeting impulsivity-related neural mechanisms for improved executive control.
Collapse
Affiliation(s)
| | - Bryan K. Tolliver
- Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston
| | - Helena M. Brenner
- Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston
| | - Raymond F. Anton
- Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston
| | - James J. Prisciandaro
- Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston
| |
Collapse
|
5
|
On the Role of Stimulus-Response Context in Inhibitory Control in Alcohol Use Disorder. J Clin Med 2022; 11:jcm11216557. [DOI: 10.3390/jcm11216557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 10/29/2022] [Accepted: 11/02/2022] [Indexed: 11/11/2022] Open
Abstract
The behavioral and neural dynamics of response inhibition deficits in alcohol use disorder (AUD) are still largely unclear, despite them possibly being key to the mechanistic understanding of the disorder. Our study investigated the effect of automatic vs. controlled processing during response inhibition in participants with mild-to-moderate AUD and matched healthy controls. For this, a Simon Nogo task was combined with EEG signal decomposition, multivariate pattern analysis (MVPA), and source localization methods. The final sample comprised n = 59 (32♂) AUD participants and n = 64 (28♂) control participants. Compared with the control group, AUD participants showed overall better response inhibition performance. Furthermore, the AUD group was less influenced by the modulatory effect of automatic vs. controlled processes during response inhibition (i.e., had a smaller Simon Nogo effect). The neurophysiological data revealed that the reduced Simon Nogo effect in the AUD group was associated with reduced activation differences between congruent and incongruent Nogo trials in the inferior and middle frontal gyrus. Notably, the drinking frequency (but not the number of AUD criteria we had used to distinguish groups) predicted the extent of the Simon Nogo effect. We suggest that the counterintuitive advantage of participants with mild-to-moderate AUD over those in the control group could be explained by the allostatic model of drinking effects.
Collapse
|
7
|
Konjusha A, Colzato L, Ghin F, Stock A, Beste C. Auricular transcutaneous vagus nerve stimulation for alcohol use disorder: A chance to improve treatment? Addict Biol 2022; 27:e13202. [DOI: 10.1111/adb.13202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 05/21/2022] [Accepted: 06/09/2022] [Indexed: 11/26/2022]
Affiliation(s)
- Anyla Konjusha
- Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine TU Dresden Dresden Germany
- University Neuropsychology Center, Faculty of Medicine TU Dresden Dresden Germany
| | - Lorenza Colzato
- Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine TU Dresden Dresden Germany
- University Neuropsychology Center, Faculty of Medicine TU Dresden Dresden Germany
| | - Filippo Ghin
- Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine TU Dresden Dresden Germany
- University Neuropsychology Center, Faculty of Medicine TU Dresden Dresden Germany
| | - Ann‐Kathrin Stock
- Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine TU Dresden Dresden Germany
- University Neuropsychology Center, Faculty of Medicine TU Dresden Dresden Germany
- Biopsychology, Faculty of Psychology TU Dresden Dresden Germany
| | - Christian Beste
- Cognitive Neurophysiology, Department of Child and Adolescent Psychiatry, Faculty of Medicine TU Dresden Dresden Germany
- University Neuropsychology Center, Faculty of Medicine TU Dresden Dresden Germany
| |
Collapse
|